Clinical trial NCT04986202: Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
Official title: A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for Up to 48 Weeks in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Heart Failure With Preserved Ejection Fraction
Keywords: Heart failure
Heart failure with preserved ejection fraction
HFpEF
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2021-08-02
Enrollment: 711
Sex: ALL
Minimum age (years): 40
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomised, double-blind, placebo-controlled, multi-center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fraction \> 40%. The study will consist of 2 separate parts, Part A and Part B, approximately 660 participants will be randomised in Part A, 820 in Part B.


Eligibility criteria: Inclusion Criteria:

Part A

1. ≥ 40 to ≤ 85 years of age, at the time of signing the informed consent.
2. Documented stable symptomatic HF (New York Heart Association Class II-IV) for at least 1 month at Screening (Visit 1) (transient HF in the setting of an MI does not qualify), with a medical history of typical symptoms of HF and receiving optimal therapy for HF as determined by the health-care physician.
3. LVEF \> 40% at Screening (Visit 1). All participants will undergo a local echocardiogram at the Screening (Visit 1) with central reading to confirm the LVEF \> 40% eligibility criteria before randomisation.
4. 6MWD ≥ 30 meters and ≤ 400 meters at Screening (Visit 1) and Randomisation (Visit 3). Difference in 6MWD between Screening and Randomisation must be \< 50 meters.
5. KCCQ-TSS ≤ 90 points at Screening (Visit 1) and Randomisation (Visit 3)
6. NT-proBNP ≥ 250 pg/mL (sinus rhythm) or ≥ 500 pg/mL (atrial fibrillation/flutter) at Screening (Visit 1) for patients with BMI ≤30 kg/m2.

NT-proBNP ≥ 200 pg/mL (sinus rhythm) or ≥ 400 pg/mL (atrial fibrillation/flutter) at Screening (Visit 1) for patients with BMI \> 30 kg/m2.

The ECG performed at Screening should be used for heart rhythm evaluation.

7.At least one of the following:

1. Structural heart disease, ie, LA enlargement and/or left ventricular hypertrophy at the echocardiogram performed at Screening (Visit 1). Left atrial enlargement is defined by at least 1 of the following: LA width (diameter) ≥ 3.8 cm or LA length ≥ 5.0 cm, or LA area ≥ 20 cm2 or LA volume ≥ 55 mL or LAVI \> 34 mL/m2. Left ventricular hypertrophy is defined by septal thickness or posterior wall thickness ≥ 1.1 cm or LVMI \> 95 g/m2 in women and \> 115 g/m2 in men.
2. Spectral tissue Doppler echocardiography - E/e' ratio (average of septal and lateral) ≥ 13 at rest at the echocardiogram performed at Screening (Visit 1).
3. Indirectly estimated elevation of PASP by TRmax velocity \> 2.8 m/s (280 cm/s) (PASP \> 35 mmHg) at the echocardiogram performed at Screening (Visit 1) OR directly measured pulmonary capillary wedge pressure \> 15 mmHg at rest within the past 12 months or \> 25 mmHg at exercise documented by right heart catheterisation within 12 months prior to Screening (Visit 1).
4. HF decompensation within 6 months before Randomisation (Visit 3), defined as hospitalisation for HF or IV diuretic treatment for HF during an urgent, unscheduled visit without hospitalisation.

   8.Body mass index ≥ 18.0 kg/m2 and ≤ 45.0 kg/m2

   9.Male or female of non-childbearing potential.

   Part B
   1. Participant must be ≥ 40 to ≤ 85 years of age, at the time of signing the informed consent.
   2. Documented diagnosis of symptomatic HF (NYHA class II-IV) at Screening (Visit 1), and a medical history of typical symptoms/signs of heart failure ≥ 6 weeks before Screening (Visit 1), and receiving optimal therapy for HF as determined by the health-care physician, with at least intermittent need for diuretic treatment.
   3. LVEF \>40% and evidence of structural heart disease (ie, left ventricular hypertrophy or

      left atrial enlargement \[defined by at least one of the following:LA enlargement and/or left ventricular hypertrophy at the echocardiogram

      performed at Screening (Visit 1). Left atrial enlargement is defined by at least 1 of the following: LA width

      (diameter) ≥ 3.8 cm or LA length ≥ 5.0 cm, or LA area ≥ 20 cm2 or LA volume ≥ 55 mL or LAVI \> 34

      mL/m2. Left ventricular hypertrophy is defined by septal thickness or posterior wall thickness ≥ 1.1 cm or

      LVMI \> 95 g/m2 in women and \> 115 g/m2 in men.\]) documented by the most recent echocardiogram, or cardiac

      magnetic resonance imaging within the last 12 months prior to Screening (Visit 1). If no

      echocardiogram is available, it can be performed at Screening (Visit 1).
   4. 6MWD ≥ 30 meters and ≤ 400 meters at Screening (Visit 1) and Randomisation (Visit 2). Difference in 6MWD between Screening and Randomisation must be \< 50 meters
   5. KCCQ-TSS ≤ 90 points at Screening (Visit 1) and Randomisation (Visit 2).
   6. NT-proBNP ≥ 250 pg/mL (sinus rhythm) or ≥ 500 pg/mL (atrial fibrillation/flutter) at Screening (Visit 1) for patients with BMI ≤ 30 kg/m2. NT-proBNP ≥ 200 pg/mL (sinus rhythm) or ≥ 400 pg/mL (atrial fibrillation/flutter) at Screening (Visit 1) for patients with BMI \> 30 kg/m2. The ECG performed at Screening should be used for heart rhythm evaluation
   7. Body mass index ≥ 18.0 kg/m2 and ≤ 45.0 kg/m2
   8. Male or female of non-childbearing potential.

   Exclusion Criteria:

   Part A

   1 eGFR \< 30 mL/min/1.73m2 (Chronic Kidney Disease-Epidemiology Collaboration formula) at Screening (Visit 1).

   2. Systolic blood pressure \< 90 mmHg or ≥ 160 mmHg if not on treatment with ≥ 3 blood pressure lowering medications or ≥ 180 mmHg irrespective of treatments at Randomisation

   3. Heart rate \> 110 bpm or \< 50 bpm at Randomisation

   4. Life expectancy \< 3 years due to other reasons than cardiovascular disease.

   5. History or ongoing allergy/hypersensitivity reactions to drugs (including but not limited to rash, angioedema, acute urticaria).

   6. Presence of any disease or condition rather than HF constituting the main reason for limiting the ability to exercise/reduced exercise capacity.

   7. Current decompensated HF and/or NT-proBNP \> 5000 pg/mL at Screening (Visit 1)

   8. Documented history of ejection fraction ≤ 40%.i.e. HF with recovered ejection fraction. Transient ejection fraction decrease e.g. in the setting of an MI does not apply

   9. Any planned cardiovascular procedure (eg, coronary revascularisation, ablation of atrial fibrillation/flutter, valve repair/replacement, aortic aneurysm surgery, etc).

   10. Any cardiac event (eg, myocardial infarction, unstable angina), coronary revascularisation (percutaneous coronary intervention or coronary artery bypass grafting), ablation of atrial fibrillation/flutter, valve repair/replacement, implantation of a cardiac resynchronisation therapy device within 12 weeks prior to Screening (Visit 1) or between Screening and Randomisation. Patients who underwent a successful atrial fibrillation/flutter cardioversion, can be enrolled in the study after 4 weeks.

   14. Hb \< 110 g/L (male) and \< 100 g/L (female) or iron-deficiency with/without anaemia requiring ongoing or planned IV iron treatment.

   15. Participants with hyperthyroidism, uncontrolled hypothyroidism (including but not limited to TSH ≥10 mIU/mL), or any clinically significant thyroid disease as judged by the investigator.

   18. ALT or AST ≥ 2 × ULN at Screening (Visit 1).

   19. Pulmonary arterial hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD (ie, requiring home oxygen, chronic nebulizer therapy or chronic oral steroid therapy, or hospitalization for exacerbation of COPD requiring ventilatory support within 12 months prior to Screening (Visit 1).

   20. Any active infection requiring oral, intravenous or intramuscular treatment at Screening (Visit 1) and/or at Randomisation.

   23 Any signs or confirmation of COVID-19 infection:
   * Suspected (as judged by PI) or confirmed COVID-19 within the last 2 weeks prior to Screening (Visit 1) or at Randomisation.
   * Hospitalisation for COVID-19 within the last 12 weeks prior to Screening (Visit 1).

     24. Any concomitant medications known to be a potent CYP3A4 inducers or inhibitors, eg, itraconazole, rifampicin, clarithromycin, or propylthiouracil

     29. Previous enrolment and randomisation in the present study. (Participants who where screened and screen failed and not randomised in Part A can be screened for possible entry to Part B).

   All exclusion criteria in Part A are applicable to Part B with the following exceptions:

   Exclusion criteria 4; 19

   Exclusion Criteria specific for Part B only \[criteria numeration for Part B\]

   4. Life expectancy \< 2 years due to other reasons than cardiovascular disease.

   11. HF due to any of the following: known infiltrative cardiomyopathy (eg, amyloid, sarcoid, lymphoma, endomyocardial fibrosis), active myocarditis, constrictive pericarditis, cardiac tamponade, known genetic hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D), or uncorrected primary valvular disease.

   18. Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD (ie, requiring home oxygen, chronic nebulizer therapy or chronic oral steroid therapy, or hospitalization for exacerbation of COPD requiring ventilatory support within 12 months prior to Screening \[Visit 1\]).

Primary outcomes:
measure: Kansas City Cardiomyopathy Questionnaire -Total Symptom Score
timeFrame: Baseline - 16 weeks
measure: Kansas City Cardiomyopathy Questionnaire -Total Symptom Score
timeFrame: Baseline - 24 weeks
measure: Six Minute Walk Distance
timeFrame: Baseline - 16 weeks
measure: Six Minute Walk Distance
timeFrame: Baseline - 24 weeks
Secondary outcomes:
measure: Kansas City Cardiomyopathy Questionnaire-Total Symptom Score
timeFrame: Baseline - 24 and 48 weeks
measure: Six Minute Walk Distance
timeFrame: Baseline - 24 and 48 weeks
measure: N-terminal pro-brain natriuretic peptide (NT-proBNP)
timeFrame: Baseline - 16, 24 and 48 weeks
measure: Left ventricular global longitudinal strain (LV-GLS)
timeFrame: Baseline - 16 and 24 weeks
measure: Left atrial volume index (LAVI)
timeFrame: Baseline - 16 and 24 weeks
measure: Left ventricular mass index (LVMI)
timeFrame: Baseline - 16 and 24 weeks
measure: Pharmacokinetics (AZD4831 plasma exposure)
timeFrame: Day 1, Day 29, Day 85, Day 113, Day 169, Day 336, Day 365
measure: High sensitivity CRP (hsCRP)
timeFrame: Baseline - 16, 24 and 48 weeks
measure: Interleukin 6 (IL-6)
timeFrame: Baseline - 16, 24 and 48 weeks
measure: High sensitivity CRP (hsCRP)
timeFrame: Baseline - 24 weeks
measure: N-terminal pro-brain natriuretic peptide (NT-proBNP)
timeFrame: Baseline - 24 weeks
measure: Interleukin 6 (IL-6)
timeFrame: Baseline - 24 weeks
Other outcomes:
measure: Adverse Events
timeFrame: Baseline - week 52
measure: Vital Signs
timeFrame: Baseline - week 52
measure: Clinical Laboratory
timeFrame: Baseline - week 52
measure: Electrocardiogram (ECG)
timeFrame: Baseline - week 52
measure: Adverse Events
timeFrame: Baseline- week 52
measure: Vital Signs
timeFrame: Baseline - week 52
measure: Clinical Laboratory
timeFrame: Baseline - week 52
measure: ECG
timeFrame: Baseline - week 52
measure: AZD4831 Pharmacokinetics
timeFrame: Baseline- week 4 and 24
Locations:
city: Alexander City
country: United States
facility: Research Site
state: Alabama
city: Little Rock
country: United States
facility: Research Site
state: Arkansas
city: Sacramento
country: United States
facility: Research Site
state: California
city: Miami Beach
country: United States
facility: Research Site
state: Florida
city: Miami
country: United States
facility: Research Site
state: Florida
city: Ocala
country: United States
facility: Research Site
state: Florida
city: Evanston
country: United States
facility: Research Site
state: Illinois
city: Hazel Crest
country: United States
facility: Research Site
state: Illinois
city: Shreveport
country: United States
facility: Research Site
state: Louisiana
city: Baltimore
country: United States
facility: Research Site
state: Maryland
city: Saint Louis
country: United States
facility: Research Site
state: Missouri
city: Buffalo
country: United States
facility: Research Site
state: New York
city: New York
country: United States
facility: Research Site
state: New York
city: Rosedale
country: United States
facility: Research Site
state: New York
city: Chapel Hill
country: United States
facility: Research Site
state: North Carolina
city: Pinehurst
country: United States
facility: Research Site
state: North Carolina
city: Cleveland
country: United States
facility: Research Site
state: Ohio
city: Philadelphia
country: United States
facility: Research Site
state: Pennsylvania
city: Knoxville
country: United States
facility: Research Site
state: Tennessee
city: Tullahoma
country: United States
facility: Research Site
state: Tennessee
city: Norfolk
country: United States
facility: Research Site
state: Virginia
city: Bedford Park
country: Australia
facility: Research Site
city: Chermside
country: Australia
facility: Research Site
city: Concord
country: Australia
facility: Research Site
city: Frankston
country: Australia
facility: Research Site
city: Aalst
country: Belgium
facility: Research Site
city: Dendermonde
country: Belgium
facility: Research Site
city: Hasselt
country: Belgium
facility: Research Site
city: Huy
country: Belgium
facility: Research Site
city: Kortrijk
country: Belgium
facility: Research Site
city: Leuven
country: Belgium
facility: Research Site
city: Roeselare
country: Belgium
facility: Research Site
city: Brasilia
country: Brazil
facility: Research Site
city: Campina Grande do Sul
country: Brazil
facility: Research Site
city: Campinas
country: Brazil
facility: Research Site
city: Campinas
country: Brazil
facility: Research Site
city: Canoas
country: Brazil
facility: Research Site
city: Curitiba
country: Brazil
facility: Research Site
city: Porto Alegre
country: Brazil
facility: Research Site
city: Ribeirão Preto
country: Brazil
facility: Research Site
city: Ribeirão Preto
country: Brazil
facility: Research Site
city: Rio de Janeiro
country: Brazil
facility: Research Site
city: São Paulo
country: Brazil
facility: Research Site
city: Blagoevgrad
country: Bulgaria
facility: Research Site
city: Pleven
country: Bulgaria
facility: Research Site
city: Plovdiv
country: Bulgaria
facility: Research Site
city: Sofia
country: Bulgaria
facility: Research Site
city: Sofia
country: Bulgaria
facility: Research Site
city: Sofia
country: Bulgaria
facility: Research Site
city: Sofia
country: Bulgaria
facility: Research Site
city: Sofia
country: Bulgaria
facility: Research Site
city: Sofia
country: Bulgaria
facility: Research Site
city: Sofia
country: Bulgaria
facility: Research Site
city: Varna
country: Bulgaria
facility: Research Site
city: Guelph
country: Canada
facility: Research Site
state: Ontario
city: Newmarket
country: Canada
facility: Research Site
state: Ontario
city: Ottawa
country: Canada
facility: Research Site
state: Ontario
city: Toronto
country: Canada
facility: Research Site
state: Ontario
city: Waterloo
country: Canada
facility: Research Site
state: Ontario
city: York
country: Canada
facility: Research Site
state: Ontario
city: Chicoutimi
country: Canada
facility: Research Site
state: Quebec
city: Trois-Rivières
country: Canada
facility: Research Site
state: Quebec
city: Brno
country: Czechia
facility: Research Site
city: Broumov
country: Czechia
facility: Research Site
city: Jaromer
country: Czechia
facility: Research Site
city: Kolin
country: Czechia
facility: Research Site
city: Louny
country: Czechia
facility: Research Site
city: Plzen
country: Czechia
facility: Research Site
city: Praha 2
country: Czechia
facility: Research Site
city: Praha
country: Czechia
facility: Research Site
city: Pribram
country: Czechia
facility: Research Site
city: Zlin
country: Czechia
facility: Research Site
city: Copenhagen O
country: Denmark
facility: Research Site
city: Hvidovre
country: Denmark
facility: Research Site
city: København NV
country: Denmark
facility: Research Site
city: København
country: Denmark
facility: Research Site
city: Roskilde
country: Denmark
facility: Research Site
city: Viborg
country: Denmark
facility: Research Site
city: Århus N
country: Denmark
facility: Research Site
city: Bayonne
country: France
facility: Research Site
city: Dijon Cedex
country: France
facility: Research Site
city: La Tronche
country: France
facility: Research Site
city: Le Coudray Cedex
country: France
facility: Research Site
city: Montauban
country: France
facility: Research Site
city: Montpellier Cedex
country: France
facility: Research Site
city: Paris
country: France
facility: Research Site
city: Paris
country: France
facility: Research Site
city: Pierre Benite
country: France
facility: Research Site
city: Rennes Cedex 9
country: France
facility: Research Site
city: Saint Brieuc
country: France
facility: Research Site
city: Toulon
country: France
facility: Research Site
city: Toulouse Cedex 9
country: France
facility: Research Site
city: TOURCOING cedex
country: France
facility: Research Site
city: Balatonfüred
country: Hungary
facility: Research Site
city: Budapest
country: Hungary
facility: Research Site
city: Budapest
country: Hungary
facility: Research Site
city: Nyíregyháza
country: Hungary
facility: Research Site
city: Fukui-shi
country: Japan
facility: Research Site
city: Higashiohmi-shi
country: Japan
facility: Research Site
city: Iwakuni-shi
country: Japan
facility: Research Site
city: Kanazawa-shi
country: Japan
facility: Research Site
city: Kasugai-shi
country: Japan
facility: Research Site
city: Kishiwada-shi
country: Japan
facility: Research Site
city: Kure-shi
country: Japan
facility: Research Site
city: Kyoto-shi
country: Japan
facility: Research Site
city: Matsumoto-shi
country: Japan
facility: Research Site
city: Minami-ku
country: Japan
facility: Research Site
city: Nagano
country: Japan
facility: Research Site
city: Naha
country: Japan
facility: Research Site
city: Oita-shi
country: Japan
facility: Research Site
city: Omihachiman-shi
country: Japan
facility: Research Site
city: Otaru-shi
country: Japan
facility: Research Site
city: Sagamihara-shi
country: Japan
facility: Research Site
city: Toshima-ku
country: Japan
facility: Research Site
city: Ueda-shi
country: Japan
facility: Research Site
city: Uwajima-shi
country: Japan
facility: Research Site
city: Yokohama-shi
country: Japan
facility: Research Site
city: Amsterdam
country: Netherlands
facility: Research Site
city: Den Bosch
country: Netherlands
facility: Research Site
city: Den Haag
country: Netherlands
facility: Research Site
city: Deventer
country: Netherlands
facility: Research Site
city: Heerlen
country: Netherlands
facility: Research Site
city: Bydgoszcz
country: Poland
facility: Research Site
city: Lublin
country: Poland
facility: Research Site
city: Rzeszow
country: Poland
facility: Research Site
city: Skierniewice
country: Poland
facility: Research Site
city: Tarnów
country: Poland
facility: Research Site
city: Tczew
country: Poland
facility: Research Site
city: Tychy
country: Poland
facility: Research Site
city: Warszawa
country: Poland
facility: Research Site
city: Warszawa
country: Poland
facility: Research Site
city: Warszawa
country: Poland
facility: Research Site
city: Wołomin
country: Poland
facility: Research Site
city: Aramil
country: Russian Federation
facility: Research Site
city: Kemerovo
country: Russian Federation
facility: Research Site
city: Moscow
country: Russian Federation
facility: Research Site
city: Moscow
country: Russian Federation
facility: Research Site
city: Moscow
country: Russian Federation
facility: Research Site
city: Novosibirsk
country: Russian Federation
facility: Research Site
city: Perm
country: Russian Federation
facility: Research Site
city: St Petersburg
country: Russian Federation
facility: Research Site
city: Tver
country: Russian Federation
facility: Research Site
city: Banska Bystrica
country: Slovakia
facility: Research Site
city: Bratislava
country: Slovakia
facility: Research Site
city: Brezno
country: Slovakia
facility: Research Site
city: Kosice
country: Slovakia
facility: Research Site
city: Kosice
country: Slovakia
facility: Research Site
city: Nitra
country: Slovakia
facility: Research Site
city: Presov
country: Slovakia
facility: Research Site
city: Göteborg
country: Sweden
facility: Research Site
city: Jönköping
country: Sweden
facility: Research Site
city: Lund
country: Sweden
facility: Research Site
city: Norrköping
country: Sweden
facility: Research Site
city: Stockholm
country: Sweden
facility: Research Site
city: Stockholm
country: Sweden
facility: Research Site
city: Stockholm
country: Sweden
facility: Research Site
city: Örebro
country: Sweden
facility: Research Site
city: Kaohsiung
country: Taiwan
facility: Research Site
city: Kaohsiung
country: Taiwan
facility: Research Site
city: Kaohsiung
country: Taiwan
facility: Research Site
city: Taichung
country: Taiwan
facility: Research Site
city: Taichung
country: Taiwan
facility: Research Site
city: Taichung
country: Taiwan
facility: Research Site
city: Tainan
country: Taiwan
facility: Research Site
city: Tainan
country: Taiwan
facility: Research Site
city: Taipei 112
country: Taiwan
facility: Research Site
city: Taipei City
country: Taiwan
facility: Research Site
city: Taipei
country: Taiwan
facility: Research Site
city: Taoyuan
country: Taiwan
facility: Research Site
city: Eskisehir
country: Turkey
facility: Research Site
city: Izmir
country: Turkey
facility: Research Site
Study officials:
References: